Ionis Pharmaceuticals reported positive topline outcomes from two pivotal Phase 3 studies (CORE and CORE2) of olezarsen, targeting severe hypertriglyceridemia (sHTG). The therapy achieved up to 72% placebo-adjusted triglyceride reduction and reduced acute pancreatitis events by 85%, with favorable tolerability. The company plans to seek label expansion for patients with severely elevated triglycerides, significantly enlarging the market opportunity beyond rare familial chylomicronemia syndrome. These results position olezarsen as a potential blockbuster addressing common lipid disorders linked to cardiovascular risk.